Chemotherapy for hormone-resistant prostate cancer: Where are we today?
Chemotherapy for hormone-resistant prostate cancer: Where are we today?
About this item
Full title
Author / Creator
Publisher
India: Medknow Publications and Media Pvt. Ltd
Journal title
Language
English
Formats
Publication information
Publisher
India: Medknow Publications and Media Pvt. Ltd
Subjects
More information
Scope and Contents
Contents
Significant progress has been achieved in chemotherapy for hormone-resistant prostate cancer (HRPC) in the last five years. Although the disease was long considered to be chemoresistant, docetaxel-based regimens in particular have been shown to both palliate symptoms and prolong survival in HRPC patients. Docetaxel is now considered the best availa...
Alternative Titles
Full title
Chemotherapy for hormone-resistant prostate cancer: Where are we today?
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_4a6c8486d7ad410a99b14ef2275787a0
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4a6c8486d7ad410a99b14ef2275787a0
Other Identifiers
ISSN
0970-1591
E-ISSN
1998-3824
DOI
10.4103/0970-1591.30269
